Health News Archive - May 19, 2009
NANJING, China, May 19 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China, today reported unaudited financial results for the quarter ended March 31, 2009. Highlights -- Total revenue increased to RMB442.5 million (US$64.8 million) for the first quarter of 2009 from RMB394.6 million for the corresponding period in 2008, representing 12.1% year-over-year growth. -- Income from operations was RMB61.1 million (US$8.9 million) for the first quarter of 2009, a decrease of 38.4% from RMB99.2 million for the corresponding period in 2008. -- Net income attributable to Simcere was RMB48.2 million (US$7.1 million) for the first quarter of 2009, representing a 57.0% year-over-year decrease. -- Gross margin for the first quarter of 2009 was 82.5%, compared to 83.2% for the corresponding period
Schering-Plough Assumes Exclusive Worldwide Marketing Rights for Mometasone Furoate/Formoterol Combination for Asthma and COPD KENILWORTH, N.J., May 19 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced changes to its global collaboration with Novartis for the development and commercialization of fixed-dose combination therapies for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Online tools will help physicians determine treatment strategies NATICK, Mass.
DUBLIN, May 19 /PRNewswire/ -- - Completed Series B Total Stands at EUR21.3 m Opsona Therapeutics, a biotechnology company focused on novel therapeutic and preventative approaches to autoimmune and inflammatory diseases, today announced that Roche Venture Fund and Enterprise Ireland have committed an additional EUR3.3 million to the Series B financing announced in February this year, bringing the total round to EUR21.3 million.
TAXUS(R) Element(TM) Stent now available in select markets worldwide NATICK, Mass., May 19 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the launch of the platinum chromium TAXUS(R) Element(TM) Paclitaxel-Eluting Coronary Stent System in select markets worldwide.
NANJING, China, May 19 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic and innovative anti-cancer pharmaceuticals in China, announced today the appointment of Dr. Peng Wang as Chief Scientific Officer. Dr.
Northeast Ohio police officers, community members, and local teens unite to underscore the importance of seat belt use CLEVELAND, May 19 /PRNewswire/ -- What: Local kickoff of the 2009 "Click It or Ticket" law enforcement mobilization and performance/screening of peer-to-peer messaging created by area high schoolers. When: Tuesday, May 19, 2009Noon (free buffet lunch for media and invited guests at 11:30 AM) Where: The Cleveland House of Blues308 Euclid Avenue, Cleveland, OH 44114 Who: Interim Chief Mark Kwiatkowski, Bedford Heights Police Department.
Letter from an African Man Living with HIV/AIDS Presented to the White House "It is not morally right for the President to cut down on the U.S. global health contribution, especially on AIDS. Cutting the budget for global AIDS funding is tantamount to genocide, and Mr.
SAN DIMAS, Calif., May 19 /PRNewswire/ -- While scientists believe they are on the frontier of discovering technologies that will produce super longevity, the curse of living longer is looking older.
Agency Gains Foothold in Healthcare with Launch Campaign for Bay Harbor Podiatry Group's Revolutionary Laser Treatment for Toenail Fungus LOS ANGELES, May 19 /PRNewswire/ -- Bob Gold & Associates, Inc., a Southern California boutique public relations and marketing agency, announced today a new addition to its client roster, Bay Harbor Podiatry Group, a Torrance, Calif.-based practice that has provided cutting-edge medical treatments and personalized care for over 25 years.
- A blustering, bullying fellow; a pot-valiant braggart; a bully.